Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PETMED EXPRESS INC Board/Management Information 2016

Feb 2, 2016

34556_rns_2016-02-02_768b4046-206a-4f2c-aac9-d9cec2fdc09d.zip

Board/Management Information

Open in viewer

Opens in your device viewer

8-K 1 pets_8k.htm CURRENT REPORT html PUBLIC "-//IETF//DTD HTML//EN" Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 29, 2016

PetMed Express, Inc. (Exact name of registrant as specified in its charter) — Florida 000-28827 65-0680967
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
1441 S.W. 29 th Avenue, Pompano Beach, FL 33069
(Address of principal executive offices) (Zip Code)
(954) 979-5995
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02(e)

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On January 29 2016 , PetMed Express, Inc. (the “Company”), based on the Compensation Committee recommendation and the Board of Directors’ approval that the Company amend the existing executive employment agreement (the “Executive Employment Agreement”) of Menderes Akdag, the Company’s President and Chief Executive Officer, entered into Amendment No. 5 to the Executive Employment Agreement with Mr. Akdag (“Agreement”). The Agreement amends certain provisions of the Executive Employment Agreement as follows: the term of the Agreement will be for three years, commencing on March 16, 2016; Mr. Akdag’s salary will be increased to $600,000 per year throughout the term of the Agreement, and Mr. Akdag shall be granted 120,000 shares of restricted stock. The restricted stock will be granted on March 16, 2016, in accordance with the Company’s 2006 Restricted Stock Plan and the restrictions shall lapse ratably over a three-year period.

Item 9.01 Financial Statements and Exhibits.

(d)
10.1 – Amendment No. 5 to Executive Employment Agreement dated January 29, 2016 and effective March 16, 2016 between the Company and Menderes Akdag.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 2, 2016

PETMED EXPRESS, INC.
By: /s/ Bruce S. Rosenbloom
Name: Bruce S. Rosenbloom
Title: Chief Financial Officer

2

EXHIBIT INDEX

Exhibit No. Description
10.1 Amendment No. 5 to Executive Employment Agreement dated January 29, 2016 and effective March 16, 2016 between the Company and Menderes Akdag.

EDGAR Validation Code: 8F21B35B